Intestinal fibrosis refers to the abnormal thickening and scarring of the intestinal tissue, often resulting from chronic inflammation or injury. A specific type of this condition, colon fibrosis, involves excessive buildup of extracellular matrix in the colon, leading to tissue scarring and loss of function. Colon fibrosis is often associated with inflammatory bowel diseases (IBD) like ulcerative colitis and Crohn’s disease, where persistent inflammation triggers fibrosis, potentially causing intestinal strictures and obstructions that impair gut motility and function.
Understanding the mechanisms behind colon fibrosis is essential for developing effective treatments to manage IBD and prevent its progression. Aragen offers dextran sulfate sodium (DSS)-induced colitis mice model, a key model for studying colon fibrosis, including mechanisms of inflammatory bowel disease (IBD), and evaluating potential anti-colitis therapeutic agents, offering hope for better management of these debilitating conditions.
DSS-Induced Intestinal Fibrosis
The DSS-induced colitis model is commonly used to study chronic intestinal inflammation and fibrosis, particularly in inflammatory bowel disease (IBD), resembling human ulcerative colitis. Administering dextran sulfate sodium (DSS) in drinking water induces colonic inflammation, tissue injury, and fibrosis, making it valuable for researching disease mechanisms and testing new treatments. Aragen offers expert preclinical services to support drug discovery and therapeutic evaluation for IBD and related disorders.
DSS water exposure for 7 days
(male C57BL/6 mice)
Regular water exposure for 14 days
(Repeat DSS/water cycle 3x total
Treatment: Cyclosporine A (CsA
(Can be before DSS or mid-cycle)
In vivo analysis
(Body weights, fecal scoring, observation)
Terminate study/harvest organs
(Blood, serum, spleen, and colon)
Ex vivo analysis
(CBC analysis, spleen weight and length, colon weight and length, liver enzymes, histology, hydroxyproline
Report
